{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:32:55Z","timestamp":1793795575134,"version":"4.6.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.rpth.2026.103416","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:48:57Z","timestamp":1774658937000},"page":"103416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1028-5416","authenticated-orcid":false,"given":"Andrew D.","family":"Leavitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Mahlangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Raheja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Symington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris V.","family":"Quon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Giermasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel S.","family":"Key","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn M.","family":"Millar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Pipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Chieh","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Klamroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Chambost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Majerus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Pepperell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Wee","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantia-Maria","family":"Chavele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareth C.","family":"Ozelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.103416_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103416_bib2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2147\/PPA.S202773","article-title":"Real-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom","volume":"13","author":"Carroll","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.rpth.2026.103416_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/hae.13377","article-title":"Impact of pain and functional impairment in US adults with haemophilia: patient-reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P-FiQ) study","volume":"24","author":"Kempton","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103416_bib4","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/hae.12545","article-title":"Haemophilia Experiences, Results and Opportunities (HERO) study: treatment-related characteristics of the population","volume":"21","author":"Nugent","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103416_bib5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","article-title":"The impact of severe haemophilia and the presence of target joints on health-related quality-of-life","volume":"16","author":"O\u2019Hara","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.rpth.2026.103416_bib6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hae.13449","article-title":"Joint disease in haemophilia: pathophysiology, pain and imaging","volume":"24","author":"van Vulpen","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103416_bib7","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.24220","article-title":"Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18-30 years) with hemophilia","volume":"90","author":"Witkop","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2026.103416_bib8","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.103416_bib9","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.3390\/jcm10245959","article-title":"Real-world rates of bleeding, factor VIII use, and quality of life in individuals with severe haemophilia A receiving prophylaxis in a prospective, noninterventional study","volume":"10","author":"Kenet","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.rpth.2026.103416_bib10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103416_bib11","first-page":"1687","article-title":"Patient and parent preferences for characteristics of prophylactic treatment in hemophilia","volume":"9","author":"Furlan","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.rpth.2026.103416_bib12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/hae.14304","article-title":"Patients\u2019 and parents\u2019 satisfaction with, and preference for, haemophilia A treatments: a cross-sectional, multicentre, observational study","volume":"27","author":"Park","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103416_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40271-019-00395-6","article-title":"Patient perspectives on novel treatments in haemophilia: a qualitative study","volume":"13","author":"van Balen","year":"2020","journal-title":"Patient"},{"key":"10.1016\/j.rpth.2026.103416_bib14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ymthe.2017.12.009","article-title":"Gene therapy with BMN 270 results in therapeutic levels of FVIII in mice and primates and normalization of bleeding in hemophilic mice","volume":"26","author":"Bunting","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.rpth.2026.103416_bib15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2026.103416_bib16","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103416_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103416_bib18","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-Factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103416_bib19","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103416_bib22","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103416_bib23","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","article-title":"Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"22","author":"Madan","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103416_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102615","article-title":"Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial","volume":"8","author":"Leavitt","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103416_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241304645","article-title":"Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy: a post hoc analysis of the GENEr8-1 phase III trial","volume":"15","author":"Quon","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2026.103416_bib26","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1182\/blood.2020005683","article-title":"Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy","volume":"136","author":"Rosen","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.103416_bib27","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1016\/j.jtha.2023.08.032","article-title":"Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1","volume":"21","author":"O\u2019Mahony","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103416_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/PROM.S357555","article-title":"Psychometric validation of the Haemo-QOL-A in participants with hemophilia A treated with gene therapy","volume":"13","author":"Quinn","year":"2022","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.rpth.2026.103416_bib29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ejh.13027","article-title":"Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the pain, functional impairment, and quality of life (P-FiQ) study","volume":"100","author":"Buckner","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.rpth.2026.103416_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12567","article-title":"Living with a \u201chemophilia-free mind\u201d \u2013 the new ambition of hemophilia care?","volume":"5","author":"Krumb","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103416_bib31","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in hemophilia","volume":"11","author":"Thornburg","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.rpth.2026.103416_bib32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/hae.13754","article-title":"From the voices of people with haemophilia A and their caregivers: challenges with current treatment, their impact on quality of life and desired improvements in future therapies","volume":"25","author":"Wiley","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103416_bib33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/hae.14278","article-title":"Evidence of a disability paradox in patient-reported outcomes in haemophilia","volume":"27","author":"O\u2019Hara","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103416_bib34","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1007\/s11136-021-02846-w","article-title":"Response shift in patient-reported outcomes: definition, theory, and a revised model","volume":"30","author":"Vanier","year":"2021","journal-title":"Qual Life Res"},{"key":"10.1016\/j.rpth.2026.103416_bib35","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.ymthe.2024.05.033","article-title":"Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A","volume":"32","author":"Long","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.rpth.2026.103416_bib36","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jtha.2024.12.038","article-title":"Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study","volume":"23","author":"Ozelo","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103416_bib37","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1089\/hum.2023.162","article-title":"Circumventing B cell responses to allow for redosing of adeno-associated virus vectors","volume":"35","author":"Ertl","year":"2024","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.rpth.2026.103416_bib38","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/hae.15071","article-title":"Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A","volume":"30","author":"Symington","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103416_bib39","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1089\/hum.2024.236","article-title":"Recombinant adeno-associated virus integration profiles in non-human primates and gene therapy participants after treatment with valoctocogene roxaparvovec","volume":"36","author":"Russell","year":"2025","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.rpth.2026.103416_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101294","article-title":"The longitudinal kinetics of AAV5 vector integration profiles and evaluation of clonal expansion in mice","volume":"32","author":"Ismail","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.rpth.2026.103416_bib41","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/hae.14936","article-title":"Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment","volume":"30","author":"Symington","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103416_bib42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","article-title":"The clinical landscape for AAV gene therapies","volume":"20","author":"Kuzmin","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.rpth.2026.103416_bib43","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/d41573-021-00164-x","article-title":"Gene therapy community grapples with toxicity issues, as pipeline matures","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.rpth.2026.103416_bib44","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/hae.14818","article-title":"Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis","volume":"29","author":"Astermark","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103416_bib45","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/hae.15025","article-title":"Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: a simulation study for individuals with severe haemophilia A","volume":"30","author":"Agarwal","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103416_bib46","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s12325-024-02834-9","article-title":"Comparative effectiveness of valoctocogene roxaparvovec and prophylactic factor VIII replacement in severe hemophilia A","volume":"41","author":"Oldenburg","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.rpth.2026.103416_bib47","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/bloodadvances.2022008948","article-title":"Valoctocogene roxaparvovec gene transfer in participants with HIV","volume":"7","author":"Ragni","year":"2023","journal-title":"Blood Adv"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926000749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926000749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:14:26Z","timestamp":1790723666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926000749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2475037926000749"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103416","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103416"}}